Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04032080 · ClinicalTrials.gov registry record · Phase 2
LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
A Phase 2 study, sponsored by Baylor Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04032080 is a Phase 2 study that has completed, run by Baylor Research Institute. The registered enrollment target is 10 participants.
The verdict
NCT04032080, a Phase 2 study, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study evaluates efficacy of LY3023414 and prexasertib in patients with metastatic triple negative breast cancer.
Interventions
- COMBINATION_PRODUCT Drug 1: LY3023414; Drug 2: Prexasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-09-05 |
| Est. Completion | 2022-11-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04032080
The ClinicalTrials.gov registry entry for NCT04032080 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Drug 1: LY3023414; Drug 2: Prexasertib is the first listed.
NCT04032080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04032080 about?
NCT04032080 is a clinical study titled "LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer". This study evaluates efficacy of LY3023414 and prexasertib in patients with metastatic triple negative breast cancer.
What is the current status of trial NCT04032080?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2019-09-05. Estimated completion is 2022-11-26.
What interventions are being tested in trial NCT04032080?
The interventions under investigation include: Drug 1: LY3023414; Drug 2: Prexasertib (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04032080?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.